Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06207370 · ClinicalTrials.gov registry record · Phase 2
Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
A Phase 2 study of Babesiosis, sponsored by 60 Degrees Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT06207370 is a Phase 2 study of Babesiosis that is actively recruiting participants, run by 60 Degrees Pharmaceuticals. The registered enrollment target is 33 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06207370, a Phase 2 study of Babesiosis, is actively recruiting participants, sponsored by 60 Degrees Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a double-blind, randomized, multisite, placebo-controlled trial comparing the safety and efficacy of TQ versus placebo in patients hospitalized for babesiosis with low risk for relapsing disease who will also be administered a standard-of-care antimicrobial regimen (A/A) that is recommended in the 2020 IDSA guideline on the diagnosis and management of babesiosis.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Tafenoquine
Study Locations (1)
Massachusetts
- Tufts Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-06-17 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06207370
The ClinicalTrials.gov registry entry for NCT06207370 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 60 Degrees Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Babesiosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06207370 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06207370 about?
NCT06207370 is a clinical study titled "Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis". This study is a double-blind, randomized, multisite, placebo-controlled trial comparing the safety and efficacy of TQ versus placebo in patients hospitalized for babesiosis with low risk for relapsing disease who will also be administered a standard-of-care antimicrobial regimen (A/A) that is recomm...
What is the current status of trial NCT06207370?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2024-06-17. Estimated completion is 2027-07-01.
What conditions does trial NCT06207370 study?
This clinical trial studies the following conditions: Babesiosis.
What interventions are being tested in trial NCT06207370?
The interventions under investigation include: Placebo (OTHER), Tafenoquine (DRUG).
Who is sponsoring clinical trial NCT06207370?
This trial is sponsored by 60 Degrees Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06207370 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.